Literature DB >> 28153086

Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction.

Colin L Sweeney1, Jizhong Zou2, Uimook Choi3, Randall K Merling3, Alexander Liu3, Aaron Bodansky3, Sandra Burkett4, Jung-Woong Kim5, Suk See De Ravin3, Harry L Malech3.   

Abstract

X-linked chronic granulomatous disease (X-CGD) is an immune deficiency resulting from defective production of microbicidal reactive oxygen species (ROS) by phagocytes. Causative mutations occur throughout the CYBB gene, resulting in absent or defective gp91phox protein expression. To correct CYBB exon 5 mutations while retaining normal gene regulation, we utilized TALEN or Cas9 for exon 5 replacement in induced pluripotent stem cells (iPSCs) from patients, which restored gp91phox expression and ROS production in iPSC-derived granulocytes. Alternate approaches for correcting the majority of X-CGD mutations were assessed, involving TALEN- or Cas9-mediated insertion of CYBB minigenes at exon 1 or 2 of the CYBB locus. Targeted insertion of an exon 1-13 minigene into CYBB exon 1 resulted in no detectable gp91phox expression or ROS activity in iPSC-derived granulocytes. In contrast, targeted insertion of an exon 2-13 minigene into exon 2 restored both gp91phox and ROS activity. This demonstrates the efficacy of two correction strategies: seamless repair of specific CYBB mutations by exon replacement or targeted insertion of an exon 2-13 minigene to CYBB exon 2 while retaining exon/intron 1. Furthermore, it highlights a key issue for targeted insertion strategies for expression from an endogenous promoter: retention of intronic elements can be necessary for expression. Published by Elsevier Inc.

Entities:  

Keywords:  CRISPR; TALEN; X-linked chronic granulomatous disease; iPSC; intron; targeted correction

Mesh:

Substances:

Year:  2017        PMID: 28153086      PMCID: PMC5368476          DOI: 10.1016/j.ymthe.2016.11.012

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  40 in total

1.  Controlled expression of transgenes introduced by in vivo electroporation.

Authors:  Takahiko Matsuda; Constance L Cepko
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-05       Impact factor: 11.205

2.  Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells.

Authors:  Randall K Merling; Colin L Sweeney; Uimook Choi; Suk See De Ravin; Timothy G Myers; Francisco Otaizo-Carrasquero; Jason Pan; Gilda Linton; Lifeng Chen; Sherry Koontz; Narda L Theobald; Harry L Malech
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

3.  Generation of functionally mature neutrophils from induced pluripotent stem cells.

Authors:  Colin L Sweeney; Randall K Merling; Uimook Choi; Debra Long Priel; Douglas B Kuhns; Hongmei Wang; Harry L Malech
Journal:  Methods Mol Biol       Date:  2014

4.  A quantitative analysis of intron effects on mammalian gene expression.

Authors:  Ajit Nott; Shlomo H Meislin; Melissa J Moore
Journal:  RNA       Date:  2003-05       Impact factor: 4.942

5.  Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Authors:  Axel Schambach; Jens Bohne; Saurabh Chandra; Elke Will; Geoffrey P Margison; David A Williams; Christopher Baum
Journal:  Mol Ther       Date:  2005-10-12       Impact factor: 11.454

6.  Introns increase transcriptional efficiency in transgenic mice.

Authors:  R L Brinster; J M Allen; R R Behringer; R E Gelinas; R D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

7.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

8.  Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting.

Authors:  Tomas Cermak; Erin L Doyle; Michelle Christian; Li Wang; Yong Zhang; Clarice Schmidt; Joshua A Baller; Nikunj V Somia; Adam J Bogdanove; Daniel F Voytas
Journal:  Nucleic Acids Res       Date:  2011-04-14       Impact factor: 16.971

9.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.

Authors:  Kosuke Yusa; S Tamir Rashid; Helene Strick-Marchand; Ignacio Varela; Pei-Qi Liu; David E Paschon; Elena Miranda; Adriana Ordóñez; Nicholas R F Hannan; Foad J Rouhani; Sylvie Darche; Graeme Alexander; Stefan J Marciniak; Noemi Fusaki; Mamoru Hasegawa; Michael C Holmes; James P Di Santo; David A Lomas; Allan Bradley; Ludovic Vallier
Journal:  Nature       Date:  2011-10-12       Impact factor: 49.962

10.  Functional Restoration of gp91phox-Oxidase Activity by BAC Transgenesis and Gene Targeting in X-linked Chronic Granulomatous Disease iPSCs.

Authors:  Magdalena Laugsch; Maria Rostovskaya; Sergiy Velychko; Cornelia Richter; Ariane Zimmer; Barbara Klink; Evelin Schröck; Michael Haase; Katrin Neumann; Sebastian Thieme; Joachim Roesler; Sebastian Brenner; Konstantinos Anastassiadis
Journal:  Mol Ther       Date:  2015-08-28       Impact factor: 11.454

View more
  16 in total

1.  A New Chapter on Targeted Gene Insertion for X-CGD: Do Not Skip the Intro(n).

Authors:  Giorgia Santilli; Adrian J Thrasher
Journal:  Mol Ther       Date:  2017-01-18       Impact factor: 11.454

Review 2.  Advances and highlights in primary immunodeficiencies in 2017.

Authors:  Javier Chinen; Morton J Cowan
Journal:  J Allergy Clin Immunol       Date:  2018-08-29       Impact factor: 10.793

Review 3.  Gene Editing in Human Haematopoietic Stem Cells for the Treatment of Primary Immunodeficiencies.

Authors:  Sameer Bahal; Klesti Karaxhuku; Giorgia Santilli
Journal:  Mol Diagn Ther       Date:  2022-10-14       Impact factor: 4.476

Review 4.  Future of Care for Patients With Chronic Granulomatous Disease: Gene Therapy and Targeted Molecular Medicine.

Authors:  Michael D Keller; Luigi D Notarangelo; Harry L Malech
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-09       Impact factor: 3.164

5.  Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR/Cas9 with 53BP1 inhibition for enhanced homology-directed repair.

Authors:  Colin L Sweeney; Mara Pavel-Dinu; Uimook Choi; Julie Brault; Taylor Liu; Sherry Koontz; Linhong Li; Narda Theobald; Janet Lee; Ezekiel A Bello; Xiaolin Wu; Ronald J Meis; Gary A Dahl; Matthew H Porteus; Harry L Malech; Suk See De Ravin
Journal:  Gene Ther       Date:  2021-03-12       Impact factor: 5.250

6.  CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes.

Authors:  Julie Brault; Taylor Liu; Ezekiel Bello; Siyuan Liu; Colin L Sweeney; Ronald J Meis; Sherry Koontz; Cristina Corsino; Uimook Choi; Guillaume Vayssiere; Marita Bosticardo; Kennichi Dowdell; Cicera R Lazzarotto; Aaron B Clark; Luigi D Notarangelo; Juan C Ravell; Michael J Lenardo; Benjamin P Kleinstiver; Shengdar Q Tsai; Xiaolin Wu; Gary A Dahl; Harry L Malech; Suk See De Ravin
Journal:  Blood       Date:  2021-12-30       Impact factor: 25.476

7.  Gene Editing Rescues In vitro T Cell Development of RAG2-Deficient Induced Pluripotent Stem Cells in an Artificial Thymic Organoid System.

Authors:  Cameron L Gardner; Mara Pavel-Dinu; Kerry Dobbs; Marita Bosticardo; Paul K Reardon; Justin Lack; Suk See DeRavin; Kent Le; Ezekiel Bello; Francesca Pala; Ottavia M Delmonte; Harry Malech; Amelie Montel-Hagan; Gay Crooks; Oreste Acuto; Matthew H Porteus; Luigi D Notarangelo
Journal:  J Clin Immunol       Date:  2021-03-01       Impact factor: 8.542

Review 8.  Editing the genome of hiPSC with CRISPR/Cas9: disease models.

Authors:  Andrew R Bassett
Journal:  Mamm Genome       Date:  2017-03-16       Impact factor: 2.957

Review 9.  Chronic Granulomatous Disease: a Comprehensive Review.

Authors:  Hsin-Hui Yu; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2021-10       Impact factor: 8.667

Review 10.  Recent advances in understanding and treating chronic granulomatous disease.

Authors:  Andrew Gennery
Journal:  F1000Res       Date:  2017-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.